Accelerate Diagnostics - AXDX Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last twelve months. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" AXDX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AXDX, but not buy additional shares or sell existing shares.
View AXDX analyst ratings or view top-rated stocks.

2 brokerages have issued twelve-month target prices for Accelerate Diagnostics' shares. Their AXDX share price forecasts range from $1.00 to $1.00. On average, they expect the company's stock price to reach $1.00 in the next year. This suggests that the stock has a possible downside of 59.8%.
View analysts price targets for AXDX or view top-rated stocks among Wall Street analysts.

Accelerate Diagnostics' stock was trading at $5.22 at the start of the year. Since then, AXDX stock has decreased by 52.3% and is now trading at $2.49.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our AXDX earnings forecast.

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) issued its earnings results on Monday, August, 15th. The medical research company reported ($0.23) EPS for the quarter, beating analysts' consensus estimates of ($0.28) by $0.05. During the same period in the previous year, the firm earned ($0.36) EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), Gilead Sciences (GILD), BIOLASE (BIOL), Alibaba Group (BABA), AT&T (T), AbbVie (ABBV) and Micron Technology (MU).

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

Accelerate Diagnostics' stock is owned by a number of institutional and retail investors. Top institutional investors include Griffin Asset Management Inc. (5.72%), Citadel Advisors LLC (0.00%), JPMorgan Chase & Co. (0.54%), Belpointe Asset Management LLC (0.50%), Davidson Kempner Capital Management LP (0.36%) and State Street Corp (0.35%). Insiders that own company stock include Hany Massarany, Jack Phillips, Jack W Schuler, Romney Humphries, Ron Price and Steven Reichling.
View institutional ownership trends.

Shares of AXDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AXDX stock can currently be purchased for approximately $2.49.

Accelerate Diagnostics (NASDAQ:AXDX) has a market capitalization of $173.46 million and generates $11.78 million in revenue each year. The medical research company earns $-77,700,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis.

The company employs 220 workers across the globe.

Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The official website for the company is acceleratediagnostics.com. The medical research company can be reached via phone at (520) 365-3100, via email at investors@axdx.com, or via fax at 520-269-6580.